Kennedy Capital Management’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
Other funds holding VRDN
KCM
Kennedy Capital Management's VRDN Position: Q3 2026 in Review
Kennedy Capital Management opened a new position in Viridian Therapeutics (VRDN) in Q3 2026: 294,947 shares worth $6.07M. The stake represents 0.11% of the portfolio and ranks #288 among its holdings. This is a return to the name: Kennedy Capital Management previously reported a position in VRDN as recently as Q3 2018.
Kennedy Capital Management first reported a position in VRDN in Q2 2018 and has held it in 3 quarters since. 235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.
- Kennedy Capital Management held 294,947 shares of Viridian Therapeutics worth $6.07M as of Q3 2026.
- Viridian Therapeutics was a new Kennedy Capital Management position in Q3 2026.
- Viridian Therapeutics made up 0.11% of Kennedy Capital Management's portfolio in Q3 2026, its #288 holding.
- Kennedy Capital Management first reported a position in Viridian Therapeutics in Q2 2018 and has held it in 3 quarters since.
- 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.
Based on Kennedy Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.